As cancer is one of the leading causes of death worldwide, the need for compounds to induce apoptosis in cancer cells becomes prominent. Previous technologies have had limited applications in that they target few cancers. Other challenges include finding a way to induce apoptosis in cancer cells but not normal cells. This technology addresses those needs by providing a safe way to induce apoptosis in only cancer and transformed cells.
DZNep, a S-adenosylhomocysteine hydrolase (SAHH) inhibitor that is also a histone methylation inhibitor, has been shown to possess anti-cancer effects by selectively inducing apoptosis in cancer and transformed cells but not in normal cells. It accomplishes this by the following:
Depleting the PRC2 complex (EZH2 complex), which has been shown to promote cell proliferation, invasion and metastasis in multiple human cancers.
Combining with TSA to induce DACT3 and abrogate Dvl2-Wnt/ß-catenin signaling.
Combining with HDAC inhibitor to reverse oncogenic reprogramming.
Licensing, Co-Development, Start Up Company.